Supernus Pharmaceuticals (SUPN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Voting matters and shareholder proposals
Election of two directors, Frederick M. Hudson and Charles W. Newhall, III, for three-year terms is proposed, with board recommendation to vote FOR both nominees.
Advisory (non-binding) vote on executive compensation is included, with board recommendation to vote FOR.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026, is proposed, with board recommendation to vote FOR.
Proposal to amend the 2021 Equity Incentive Plan to increase the number of shares available under the plan, with board recommendation to vote FOR.
Board of directors and corporate governance
Board recommends all proposals and nominees, indicating unified governance support for the agenda.
Executive compensation and say-on-pay
Shareholders are asked to approve, on a non-binding basis, the compensation paid to named executive officers.
Latest events from Supernus Pharmaceuticals
- All-stock merger to form a diversified CNS biopharma leader with $2.2B in commercial assets.SUPN
Proxy filing - Merger forms a CNS leader with $2.2B revenue, 11 medicines, and major cost synergies.SUPN
Proxy filing - Supernus and Indivior to merge as equals, forming a CNS leader with $2.2B revenue and $1B dividend.SUPN
Proxy filing - Merger creates a $2.2B CNS leader with $125M synergies, $1B dividend, and strong growth drivers.SUPN
Q2 2026 & Merger - Strong CNS portfolio growth, robust financials, and expanding market opportunities ahead.SUPN
Jefferies Global Healthcare Conference 2026 - Prescriptions rebounded post-supply issues; Qelbree and ONAPGO show strong growth and market potential.SUPN
Bank of America Global Healthcare Conference 2026 - Q1 2026 revenue up 39% to $207.7M, net loss narrows, and CNS portfolio expands.SUPN
Q1 2026 - Virtual meeting to vote on directors, pay, auditor, and equity plan; strong governance focus.SUPN
Proxy filing - Record 2025 revenue and strong growth in key products set the stage for robust 2026 outlook.SUPN
Q4 2025